Friday, 20 November 2026
M
Meridian Globe
Live briefing
[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet

SK 海力士回应“HBM4 良率已突破 70%”:商业机密,不便披露

Source IT之家17h ago
Summary

This item is a 中文-language original; headline and summary shown as published.

IT之家 11 月 19 日消息,日前有消息称,SK 海力士 HBM4 的良率已突破 70%。对于上述传闻及未来预期良率何时进一步突破等,财闻向 SK 海力士方面进行求证,相关负责人回应称:公司始终致力于通过持续的技术创新和工艺优化,为客户提供高质量、高性能的存储解决方案,HBM 相关产品的具体良率数据及未来预期 属…

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Tech
Region
China
Language
中文
Item ID
tech-149b399a

Comments 0 comments

No comments yet. Be the first.

SK 海力士回应“HBM4 良率已突破 70%”:商业机密,不便披露 · Meridian Globe